- Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phaseYang, Sen; Zhang, Xiaoshuai; Gale, Robert Peter; Du, Xin; Chen, Chun-yan; Weng, Jian-yu; Huang, Jian; Li, Fei; Zeng, Yun; Xiao, Zhen; Hu, Jian-da; Yang, Li-jie; Liu, Zhuo-gang; Li, Guo-hui; Sun, Xiu-li; Yang, Wei; Feng, Ru; Han, Yan-qiu; Jing, Yu; Xu, Na; Liu, Xiao-li; Liu, Zhen-fang; Wang, Xiao-dong; Wu, Shi-xin; Liang, Rong; Zhang, Yan-li; Yang, Yun-fan; Zhu, Huan-ling; Pan, Ling; Meng, Li; Zhao, Yan-hong; Yi, Hai; Liu, Yi-lan; Zhang, Wei-hua; Zheng, Yuan-jun; Zhou, Ze-ping; Chen, Su-ningAmerican Journal of Hematology, 2023, 98(7): E183-E186.
- Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase InhibitorZhang, Xiaoshuai; Liu, Bingcheng; Huang, Jian; Zhang, Gongli; Liu, Xiaoli; Xu, Na; Li, Weiming; Du, Xin; Weng, Jianyu; Lin, Hai; Liang, Rong; Chen, Chunyan; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Wang, Xiaodong; Li, Guohui; Liu, Zhuogang; Liu, Zhenfang; Hu, Jianda; Liu, Chunshui; Fei, Li; Yang, Wei; Meng, Li; Gale, Robert Peter; Huang, Xiao Jun; Jiang, Qian64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.
- Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaChen, Suning; Zhang, Yanli; Xu, Na; Sun, Hui; Li Weiming; Yang, Yunfan; Zhu, Zunmin; Duan, Minghui; Qian, Sixuan; Zhu, Yu; Luo, Jianmin; Wang, Xiaodong; Yang, Wei; Gu, Weiying; Li, Fei; Liu, Bingcheng; Xu, Yunxiao; Liu, Zhenfang; Wang, Chunling; Jiang, Yirong; Meng, Li; Wen, Qin; Xu, Yanli; Zou, Xingli; Wang, Wei; Xue, Yan; Xu, Hao; Bi, Kehong; Zhou, Fuling; Ma, Liangming; Fu, Rong; Ouyang, Guifang; Ding, Kaiyang; Wu, Depei65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
22阅读
